Economic evaluation of the SP142 versus 22C3 PD-L1 assays in the treatment of atezolizumab plus nab-paclitaxel for patients with advanced triple negative breast cancer in the Brazilian private healthcare systemp
J. bras. econ. saúde (Impr.); 12 (2), 2020
Objective: The aim of the study was to demonstrate the economic impact of two PD-L1
immunohistochemistry (IHC) assays, SP142 versus 22C3, in the treatment with atezolizumab plus
nab-paclitaxel in patients with advanced triple negative breast cancer (aTNBC) in the Brazilian private
healthcare system (BPHS...
